Atwood & Palmer Inc. Invests $1.47 Million in Avanos Medical Inc (AVNS)

Atwood & Palmer Inc. acquired a new stake in shares of Avanos Medical Inc (NYSE:AVNS) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 21,396 shares of the company’s stock, valued at approximately $1,466,000.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Whittier Trust Co. acquired a new position in Avanos Medical during the third quarter valued at approximately $110,000. Public Employees Retirement System of Ohio acquired a new position in Avanos Medical during the second quarter valued at approximately $136,000. CENTRAL TRUST Co acquired a new position in Avanos Medical during the third quarter valued at approximately $167,000. Bank of Montreal Can acquired a new position in Avanos Medical during the third quarter valued at approximately $197,000. Finally, Schaper Benz & Wise Investment Counsel Inc. WI acquired a new position in Avanos Medical during the third quarter valued at approximately $205,000. Institutional investors and hedge funds own 84.04% of the company’s stock.

AVNS has been the subject of several research analyst reports. Raymond James upgraded shares of Avanos Medical from a “market perform” rating to an “outperform” rating in a research report on Tuesday, August 21st. Morgan Stanley boosted their price objective on shares of Avanos Medical from $58.00 to $60.00 and gave the company an “underweight” rating in a research report on Wednesday, August 8th. Zacks Investment Research downgraded shares of Avanos Medical from a “buy” rating to a “hold” rating in a research report on Friday, August 10th. KeyCorp boosted their price objective on shares of Avanos Medical from $66.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, August 8th. Finally, Barclays initiated coverage on shares of Avanos Medical in a research report on Monday, October 15th. They set an “equal weight” rating and a $69.00 price objective for the company. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $69.25.



AVNS traded up $0.28 during trading on Monday, hitting $56.87. 7,728 shares of the stock traded hands, compared to its average volume of 286,178. Avanos Medical Inc has a twelve month low of $41.51 and a twelve month high of $72.96. The company has a market cap of $2.68 billion, a P/E ratio of 24.58 and a beta of 1.77. The company has a debt-to-equity ratio of 0.19, a current ratio of 2.48 and a quick ratio of 2.18.

Avanos Medical (NYSE:AVNS) last announced its quarterly earnings data on Tuesday, August 7th. The company reported $0.48 EPS for the quarter, beating the consensus estimate of $0.38 by $0.10. Avanos Medical had a net margin of 11.85% and a return on equity of 7.61%. The business had revenue of $160.90 million during the quarter, compared to the consensus estimate of $157.37 million. On average, analysts expect that Avanos Medical Inc will post 1.87 earnings per share for the current fiscal year.

About Avanos Medical

Avanos Medical, Inc operates as a medical technology company that focuses on eliminating pain, speeding recovery, and preventing infection for healthcare providers and patients worldwide. Its Medical Devices segment provides a portfolio of products that focuses on respiratory and digestive health, along with surgical and interventional pain management.

Further Reading: Short Selling

Want to see what other hedge funds are holding AVNS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Avanos Medical Inc (NYSE:AVNS).

Institutional Ownership by Quarter for Avanos Medical (NYSE:AVNS)

Receive News & Ratings for Avanos Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avanos Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply